Cellectis’ (NASDAQ:CLLS) Hold Rating Reiterated at SunTrust Banks, Inc.

Cellectis S.A. (NASDAQ:CLLS)‘s stock had its “hold” rating restated by research analysts at SunTrust Banks, Inc. in a research note issued on Friday, October 6th. They presently have a $20.00 price target on the biotechnology company’s stock. SunTrust Banks, Inc.’s target price would suggest a potential downside of 28.83% from the company’s previous close.

Several other equities research analysts have also commented on the stock. BidaskClub upgraded shares of Cellectis from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Jefferies Group LLC set a $47.00 target price on shares of Cellectis and gave the company a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Wednesday, July 19th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $40.00 price objective (up previously from $33.00) on shares of Cellectis in a research note on Tuesday, September 5th. Finally, Nomura dropped their price objective on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $39.00.

Shares of Cellectis (NASDAQ:CLLS) opened at 28.10 on Friday. The company’s market capitalization is $1.01 billion. Cellectis has a 12 month low of $16.09 and a 12 month high of $32.46. The stock’s 50 day moving average is $28.15 and its 200 day moving average is $28.15.

ILLEGAL ACTIVITY WARNING: “Cellectis’ (NASDAQ:CLLS) Hold Rating Reiterated at SunTrust Banks, Inc.” was first posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/cellectis-s-a-clls-earns-hold-rating-from-suntrust-banks-inc/1700773.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLLS. Trexquant Investment LP purchased a new position in shares of Cellectis during the 1st quarter valued at approximately $214,000. Eqis Capital Management Inc. boosted its stake in shares of Cellectis by 27.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 2,287 shares during the last quarter. Sphera Funds Management LTD. boosted its stake in shares of Cellectis by 27.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock valued at $5,261,000 after buying an additional 44,100 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares during the last quarter. Finally, ARK Investment Management LLC lifted its stake in Cellectis by 79.1% during the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares during the last quarter. Hedge funds and other institutional investors own 14.82% of the company’s stock.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.